Attached files
| file | filename |
|---|---|
| EX-31.2 - EX-31.2 - NGM BIOPHARMACEUTICALS INC | ngm-ex312_1163.htm |
| EX-31.1 - EX-31.1 - NGM BIOPHARMACEUTICALS INC | ngm-ex311_7.htm |
| EX-23.1 - EX-23.1 - NGM BIOPHARMACEUTICALS INC | ngm-ex231_6.htm |
| EX-21.1 - EX-21.1 - NGM BIOPHARMACEUTICALS INC | ngm-ex211_10.htm |
| EX-10.18 - EX-10.18 - NGM BIOPHARMACEUTICALS INC | ngm-ex1018_397.htm |
| EX-10.17 - EX-10.17 - NGM BIOPHARMACEUTICALS INC | ngm-ex1017_396.htm |
| 10-K - 10-K - NGM BIOPHARMACEUTICALS INC | ngm-10k_20201231.htm |
Exhibit 32.1
CERTIFICATION PURSUANT TO
18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
Pursuant to the requirement set forth in Rule 13a-14(b) of the Securities Exchange Act of 1934, as amended, (the “Exchange Act”) and Section 1350 of Chapter 63 of Title 18 of the United States Code (18 U.S.C. § 1350), David J. Woodhouse, Principal Executive Officer of NGM Biopharmaceuticals, Inc. (the “Company”) and Siobhan Nolan Mangini, Chief Financial Officer of the Company, each hereby certifies that, to the best of his knowledge:
|
1. |
The Company’s Annual Report on Form 10-K for the year ended December 31, 2020, to which this Certification is attached as Exhibit 32.1 (the “Annual Report”), fully complies with the requirements of Section 13(a) or Section 15(d) of the Exchange Act; and |
|
2. |
The information contained in the Annual Report fairly presents, in all material respects, the financial condition and results of operations of the Company. |
Date: March 15, 2021
|
/s/ David J. Woodhouse, Ph.D. |
|
David J. Woodhouse, Ph.D. |
|
Chief Executive Officer and Director |
|
(Principal Executive Officer) |
|
/s/ Siobhan Nolan Mangini |
|
Siobhan Nolan Mangini |
|
Chief Financial Officer |
|
(Principal Financial Officer) |
This certification accompanies the Annual Report on Form 10-K to which it relates, is not deemed filed with the Securities and Exchange Commission and is not to be incorporated by reference into any filing of NGM Biopharmaceuticals, Inc. under the Securities Act of 1933, as amended, or the Exchange Act (whether made before or after the date of the Form 10-K), irrespective of any general incorporation language contained in such filing. A signed original of this written statement required by Section 906, or other document authenticating, acknowledging, or otherwise adopting the signature that appears in typed form within the electronic version of this written statement required by Section 906, has been provided to the Company and will be retained by the Company and furnished to the Securities and Exchange Commission or its staff upon request.